Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial or primary peritoneal cancer
• Completed primary therapy (surgery and chemotherapy for newly diagnosed disease) within the past 12 months and meets 1 of the following criteria:
• * Clinical or radiographic evidence of disease
• * Serologic evidence of disease
• * Initial diagnosis of stage III or IV disease AND completed anticancer therapy within the past 12 months
• At least 2 intact axillary and/or inguinal lymph node basins
• * Prior lymph node biopsy allowed provided lymphoscintigraphy demonstrates intact drainage to a node in that basin
• HLA-A1-, -A2-, or -A3-positive
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• GOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count \> 1,500/mm\^3
• Hemoglobin \> 8.0 g/dL OR
• Hematocrit \> 25%
• Platelet count ≥ 80,000/mm\^3
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal
• Hepatitis C negative
• Renal
• Not specified
• Cardiovascular
• No New York Heart Association class III or IV heart disease
• Immunologic
• HIV negative
• No active infection requiring antibiotics
• No prior or active autoimmune disorder requiring cytotoxic or immunosuppressive therapy
• No prior autoimmune disorder with visceral involvement
• No known or suspected allergy to any component of the study vaccine
• The following immunologic conditions are allowed:
• * Laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer) that is asymptomatic
• * Clinical evidence of vitiligo or other forms of depigmenting illness
• * Mild arthritis requiring non-steroidal anti-inflammatory drugs
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Weight ≥ 110 lbs
• No uncontrolled diabetes, defined as hemoglobin A1C ≥ 7%
• No active hyperthyroidism
• No current or recent (within the past year) addiction to alcohol or drugs
• No medical contraindication or other potential medical problem that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 2 weeks since prior and no concurrent allergy desensitization injections
• More than 2 weeks since prior and no concurrent growth factors (e.g., epoetin alfa or pegfilgrastim)
• More than 1 month since prior and no other concurrent immunotherapy
• More than 2 weeks since prior and no other concurrent potential immunomodulating agents, including any of the following:
• * Interferon
• * Tumor necrosis factor
• * Interleukins or other cytokines
• * Biologic response modifiers
• * Monoclonal antibodies
• No prior vaccination with all of the study peptides relevant to the patient's HLA-type
• Chemotherapy
• See Disease Characteristics
• More than 1 month since prior chemotherapy and recovered
• No concurrent cytotoxic chemotherapy
• Endocrine therapy
• More than 2 weeks since prior and no concurrent parenteral or oral corticosteroids (e.g., prednisone or albuterol)
• * Topical corticosteroids allowed
• Radiotherapy
• More than 1 month since prior radiotherapy and recovered
• Surgery
• See Disease Characteristics
• More than 1 month since prior surgery and recovered
• Other
• More than 1 month since other prior treatment and recovered
• More than 1 month since prior and no other concurrent investigational agents